Quality-of-Life Impairment in Patients with Hidradenitis Suppurativa: A Canadian Study

American Journal of Clinical Dermatology

Volumn 16, Issue 1, 2015, Pages 61-65

  Alavi, Afsaneh ^a,e   Anooshirvani, Niloofar ^b   Kim, Whan B ^c   Coutts, Pat ^d   Sibbald, R Gary ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c MCMASTER UNIVERSITY   (Canada)

^d Mississauga Wound Healing Clinic   (Canada)

^e WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANADA; CANADIAN; CASE STUDY; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; SHORT FORM 36; SUPPURATIVE HIDRADENITIS; MIDDLE AGED; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; AGED; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; MALE; MIDDLE AGED; ONTARIO; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84921739003     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.1007/s40257-014-0105-5     Document Type: Article

References (25)

1. Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J. Quality of Life Group of the French Society of Dermatology. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol. 2007;56(4):621–3.
2. Hong J, Koo B, Koo J. The psychosocial and occupational impact of chronic skin disease. Dermatol Ther. 2008;21(1):54–9.
3. Spear M. Hidradenitis suppurativa: a painful and debilitating condition. Plastic Surg Nursing. 2010;30(4):256–8.
4. Kamp S, Fiehn AM, Stenderup K, Rosada C, Pakkenberg B, Kemp K, et al. Hidradenitis suppurativa: a disease of the absent sebaceous gland? Sebaceous gland number and volume are significantly reduced in uninvolved hair follicles from patients with hidradenitis suppurativa. Br J Dermatol. 2011;164(5):1017–22.
5. Yazdanyar S, Jemec GB. Hidradenitis suppurativa: a review of cause and treatment. Curr Opin Infect Dis. 2011;24(2):118–23.
6. Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158–64.
7. Vazquez BG, Alikhan A, Weaver AL, Wetter DA, Davis MD. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Investig Dermatol. 2013;133(1):97–103.
8. Jemec GB. Hidradenitis suppurativa and immune dysregulation. Br J Dermatol. 2012;166(2):237–8.
9. Kromann C, Ibler KS, Kristiansen VB, Jemec GB. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol. 2014;94(5):553-7.
10. Ingram JR, Piguet V. Phenotypic heterogeneity in hidradenitis suppurativa (acne inversa): classification is an essential step toward personalized therapy. J Invest Dermatol. 2013;133(6):1453–6.
11. Scheinfeld N. Hidradenitis suppurativa: a practical review of possible medical treatments based on over 350 hidradenitis patients. Dermatol Online J. 2013;19(4):1.
12. Onderdijk AJ, van der Zee HH, Esmann S, Lophaven S, Dufour DN, Jemec GB, et al. Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol JEADV. 2013;27(4):473–8.
13. Kurek A, Peters EM, Chanwangpong A, Sabat R, Sterry W, Schneider-Burrus S. Profound disturbances of sexual health in patients with acne inversa. J Am Acad Dermatol. 2012;67(3):422–8, 428.e1.
14. Solarski ST. Living with hidradenitis suppurativa. Dermatol Nurs Dermatol Nurs Assoc. 2004;16(5):447–9.
15. Gold DA, Reeder VJ, Mahan MG, Hamzavi IH. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2014;70(4):699–703.
16. Reeder VJ, Mahan MG, Hamzavi IH. Ethnicity and hidradenitis suppurativa. J Investig Dermatol. 2014;134(11):2842–3.
17. Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc. 2004;9(2):169–80.
18. Ware JE Jr, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care. 1995;33(4 Suppl):AS264–79.
19. Ware JE Jr. SF-36 health survey update. Spine. 2000;25(24):3130–9.
20. Esmann S, Jemec GB. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Dermato Venereol. 2011;91(3):328–32.
21. Matusiak L, Bieniek A, Szepietowski JC. Psychophysical aspects of hidradenitis suppurativa. Acta Dermato Venereol. 2010;90(3):264–8.
22. von der Werth JM, Jemec GB. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol. 2001;144(4):809–13.
23. Matusiak L, Bieniek A, Szepietowski JC. Hidradenitis supprativa markedly decreases quality of life and professional activity. J Am Acad Dermatol. 2010;62(4):706–8, 708.e1.
24. Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus: surgical approach. In: Roenigk RK, Roeningk HH, editors. Dermatologic surgery. New York: Marcel Dekker; 1989. p. 729–39.
25. Section of Dermatology, Department of Dermatology and Wound Healing, School of Medicine, Cardiff University. Dermatology Life Quality Index (DLQI): frequently asked questions. Available from http://www.dermatology.org.uk/quality/dlqi/quality-dlqi-faqs.html. Accessed 2 Jun 2014.